Search PubMed⌕ Search

Biomedical subjects

D Albrechtsen

Publications and source records attributed to D Albrechtsen.

At least 91 records · Page 5Linked to original sources
PubMed1987

Depletion of T lymphocytes from human bone marrow. Use of magnetic monosized polymer microspheres coated with T-lymphocyte-specific monoclonal antibodies.

A new technique for depletion of T cells from bone marrow is presented. Bone marrow cells (BMC) were rosetted with magnetic monosized polystyrene microspheres coated with monoclonal antibodies (MAbs) specific for T cell CD2 and CD3 antigens. Rosetted T cells were subsequently removed from non-T cells with the aid of a magnet. This immunomagnetic separation procedure was carried out in less than 40 min and reproducibly removed T cells, leaving a maximum of 0.025% sheep-red-blood-cell (SRBC) rosette-forming cells and less than 0.02% T cells as detected by a T cell limiting dilution assay. The efficacy of the depletion procedure was further shown by flow cytometry data, by effective removal of cells from a T cell line added to the BMC prior to immunomagnetic separation, and by abrogation of interleukin 2 (IL-2)-producing capacity in T-cell-depleted BMC (BMC-T). The T cell depletion procedure provided a 43-74% recovery of non-T cells present in the Isopaque-Ficoll-isolated bone marrow mononuclear cell fraction and did not disturb the growth potential of stem cells, as assayed by hematopoietic stem cell assays.

Antibodies, Monoclonal↗
PubMed1987

No difference in outcome between 314 nontransfused and 614 transfused cadaveric renal transplant recipients: the Scandinavian experience.

Pretransplant blood transfusions had no beneficial effect on the graft survival rate, the rejection frequency, or the quality of graft function in a case material consisting of 928 cadaveric kidney transplant recipients treated with 3 different CsA dose protocols. When younger recipients, PRA-negative recipients, or recipients receiving poorly HLA-matched kidneys were analyzed separately, there was still no transfusion effect. In the most recent series, the one-year graft survival rate was 84% among 164 nontransfused patients, and in 73 nontransfused patients under 50 years of age it was 90%. We conclude that with present day immunosuppressive therapy, based on CsA, there is no case for pretreatment blood transfusions. Indeed, this practice might place the renal transplant patient at a disadvantage.

Blood Transfusion↗
PubMed1986

HLA-matching and pretransplant blood transfusions in cadaveric renal transplantation--a changing picture with cyclosporin.

613 patients were included in a study to assess the extent to which HLA-matching and pretransplant blood transfusions affect the outcome of cadaveric renal transplantation in patients treated with cyclosporin and low doses of prednisolone. Matching for the HLA-DR-antigens significantly reduced the frequency of rejection episodes, but neither HLA-matching nor pretransplant blood transfusions influenced the patient and graft survival rates.

Analysis of Variance↗
PubMed1986

Decreased natural killer cell activity versus normal natural killer cell markers in mononuclear cells from patients with smouldering leukemia.

Peripheral blood (PB) and bone marrow mononuclear cells from 23 patients with smouldering leukemia were analyzed for natural killer (NK) cell activity and various surface cell markers. Significantly reduced NK activity was detected in the patients' PB compared with the activity in the healthy controls (p less than 0.0005). A similar difference in NK cell activity between the 2 groups was also observed in bone marrow mononuclear cells (p = 0.005). In contrast, no significant differences in cells positive for the NK cell markers Leu-7 and Leu-11b were found between patients and controls, either in PB or in bone marrow. The patients' PB and bone marrow mononuclear cells had, however, a reduced percentage and absolute number of Leu 3a+ and T8+ cells. Patients with smouldering leukemia have immunological derangements which may make them predisposed for the later development of florid leukemia.

Adolescent↗
PubMed1986

HLA-matching in cyclosporine treated renal transplant recipients: a prospective Swedish-Norwegian multicenter study.

1. In this prospective study of 613 CD and 205 one haplotype mismatched LRD transplant recipients treated with CyA, there was no influence of HLA-matching (A, B, DR or combinations) on graft survival rate at one and two years. 2. Patients who successfully received HLA-DR-matched kidneys (CD or LRD) had fewer rejection episodes during the first six months after transplantation. 3. Three factors significantly reduced the cadaveric graft survival rate: (a) presence of panel reactive T-cell antibodies in a current recipient serum, (b) cold ischemia time beyond 27 hours, and (c) recipient age above 55 years. 4. The survival rate of one haplotype mismatched LRD kidneys was excellent and is considered to be the optimal treatment for uremia also in CyA-treated patients. 5. Based on this study, exchange of well HLA-matched CD kidneys to non-sensitized patients has been terminated provisionally in Scandia-transplant. Exchange of HLA-A, B-matched kidneys will be maintained, however, for sensitized patients inasmuch as this will increase the chance of obtaining a negative cross-match and possibly improve graft survival in this high-risk patient group.

Cyclosporins↗
PubMed1986

Renal transplants from HLA-haploidentical living-related donors. The influence of donor-specific transfusions and different immunosuppressive regimens.

A total of 151 potential recipients of kidney grafts from one-HLA-haplotype-mismatched MLC-positive (RR greater than 20%) donors treated during 1980-1984 was investigated. The recipients were divided retrospectively into four groups: (A) 42 patients who received pretransplant donor-specific transfusions (DST) and posttransplant azathioprine/prednisolone (DST-only); (B) 10 patients who received DST with azathioprine before and azathioprine/prednisolone after grafting (DST-aza); (C) 42 patients who received no pretreatment and azathiprione/prednisolone posttransplant (aza group) and (D) 57 patients who also received no pretreatment but cyclosporine/prednisolone posttransplant (CsA group). DST-only led to persistently positive crossmatch in nine (21%) and transient positive crossmatch in two patients, while no sensitization occurred in the DST-aza group. Posttransplant, early acute rejection episodes were frequent in the DST-only group, but no graft was lost to acute rejection during first year; one-year graft survival (GS) = 94%. Similar GS (93%) was obtained in the CsA group, while in the aza group poorer results were obtained; GS = 69%. In the DST-aza group clinical problems including serious infections were observed. As CsA treatment without DST gave as high graft survival as in the DST groups, but avoided the sensitization risk by DST alone and the bone marrow complications of DST-aza, such treatment has become our preferred therapy for haploidentical renal transplants.

Adolescent↗